TABLE 2.

Treatment-emergent adverse events

Adverse eventa	No. (%) of subjects
	Child-Pugh class			Healthy controls (n = 9)	Hepatically impaired total (n = 24)
	A (n = 8)	B (n = 8)	C (n = 8)
All subjects with adverse events	1 (13)	4 (50)	4 (50)	4 (44)	9 (38)
Gastrointestinal disorders	1 (13)	4 (50)	2 (25)	1 (11)	7 (29)
Diarrhea	1 (13)	4 (50)	2 (25)	0 (0)	7 (29)
Gastritis	0 (0)	0 (0)	0 (0)	1 (11)	0 (0)
General disorders and administration site conditions	0 (0)	0 (0)	1 (13)	0 (0)	1 (4)
Noncardiac chest pain	0 (0)	0 (0)	1 (13)	0 (0)	1 (4)
Investigations	0 (0)	0 (0)	1 (13)	1 (11)	1 (4)
Blood creatine phosphokinase increased	0 (0)	0 (0)	1 (13)	0 (0)	1 (4)
Hepatic enzyme increased	0 (0)	0 (0)	0 (0)	1 (11)	0 (0)
Nervous system disorders	0 (0)	0 (0)	1 (13)	2 (22)	1 (4)
Headache	0 (0)	0 (0)	1 (13)	2 (22)	1 (4)
Skin and subcutaneous tissue disorders	0 (0)	0 (0)	0 (0)	1 (11)	0 (0)
Rash	0 (0)	0 (0)	0 (0)	1 (11)	0 (0)

^aAdverse events are classified according to MedDRA version 15.1.